Today on Drug Discovery & Development
Weekly Gilead and Merck oral HIV regimen maintains suppression in two phase 3 trials
An investigational once-weekly tablet from Gilead and Merck maintained virologic suppression at Week 48 in two Phase 3 trials that enrolled a combined 1,209 adults with virologically suppressed HIV. The combination pairs 2 mg of Merck’s islatravir with 300 mg of Gilead’s lenacapavir. Participants assigned to the investigational arms cut treatment from seven pills a…
BMS claims pharma’s most powerful AI supercomputer. How it stacks up to Lilly’s and Roche’s.
Bristol Myers Squibb said Monday it will deploy an NVIDIA DGX SuperPOD, a prepackaged supercomputing platform that NVIDIA sells as a single standard unit, combining multiple compute racks, high-speed networking and management software into one cluster. BMS describes it as the “most powerful and energy-efficient single-owned NVIDIA infrastructure in life sciences.” That claim lands nine…
Drug Discovery and Development See More >
CEO of CDMO AustinPx on its exclusive agreement with Thermo Fisher’s Patheon division
Thermo Fisher’s Patheon division has signed an exclusive agreement with AustinPx to install the Texas CDMO’s KinetiSol technology at Patheon’s Bend, Oregon, and Cincinnati sites. AustinPx specializes in bioavailability enhancement for orally delivered small molecules, and the placement plugs into Patheon’s Quadrant 2 platform, which applies AI/ML to formulation prediction. It expands access to KinetiSol-enabled…
Top pharma companies set sustainability goals, but emissions are still increasing
SLAS 2026: Orchestration patforms, API-first instruments and the rise of semiautonomous labs
How digital tools and AI are accelerating drug discovery
Pharma 2035 Playbook: Speed, focus and conviction in an uncertain world
Sponsored Content See More >
Top Automated Dispensing Cabinets for Pharmacies: Leading Brands ComparedSimplifying workflows is essential. Individuals in the pharmacy industry may accomplish more work with fewer errors by automating medication distribution.…
How Endogenous Tagging is Reshaping Protein AnalysisUnderstanding how proteins behave inside living cells is essential for modern drug discovery. Yet many widely used approaches, particularly plasmid…
What sets oncology biosimilars apart: Anticipating key challenges in the development landscapeBy Kimberly Salgado, ICON plc Advancements in biologic therapies have greatly improved our ability to treat cancer over the last…
Advancing Pressure Protection in Biopharma: How Integrated Bypass Technology Elevates Single-Use Pump Designby Michael Irving, Xylem In pharmaceutical and biopharmaceutical manufacturing, there is zero margin for error when it comes to process…
Complexity’s counterpoint: Understanding protocol optimization In recent years, the clinical research landscape has been marked by a steady rise in protocol complexity with more endpoints…
Optimizing Data Pipelines in Life Sciences with AI-Driven Integration and FHIRSponsored by Infor. Data management in life sciences is inherently complex. Data is fragmented across multiple systems — such…
Accelerating life sciences with AI This case study is sponsored by Infor. Artificial intelligence can revolutionize clinical interoperability by building bridges across data silos. Machine…
Advancing Clinical Trials and ResearchThis case study is sponsored by Infor. In the complex landscape of clinical trials and medical research, data fragmentation remains…
Multidisciplinary approaches optimize contract drug discovery
5 Key Questions in Conducting Global Usability StudiesBy Dr Bryce G Rutter, Head Noble Consulting Services Evaluating device usability throughout the product development process is crucial. A…
Leveraging HF/UX/ID Services to Optimize the Design of Combination Devices for Arthritic HandsBy Dr. Bryce G Rutter, Head of Consulting Services Arthritis changes how people grasp and manipulate an object, reducing the…
Ask the Expert: Navigating the New FDA Rules on Laboratory Developed Tests (LDTs)The U.S. FDA released a final rule to regulate laboratory developed tests (LDTs) on May 6, 2024, making it clear…
Genomics/Proteomics See More >
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
“I remember when we decided the internet was going to cure everything, and it didn’t…it came with a certain set of problems,” said Mark Bagnall, CEO of Phenomix Sciences. GLP-1s are having a similar moment, he says. GLP-1s have been transformative for many; by 2025, more than 30 million Americans were taking them for weight…
Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Spatial biology: Transforming our understanding of cellular environments
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
Infectious Disease See More >
Weekly Gilead and Merck oral HIV regimen maintains suppression in two phase 3 trials
An investigational once-weekly tablet from Gilead and Merck maintained virologic suppression at Week 48 in two Phase 3 trials that enrolled a combined 1,209 adults with virologically suppressed HIV. The combination pairs 2 mg of Merck’s islatravir with 300 mg of Gilead’s lenacapavir. Participants assigned to the investigational arms cut treatment from seven pills a…
Oncology See More >
How ConcertAI turned CancerLinQ into a point-of-care oncology intelligence platform
More than a decade ago, the American Society of Clinical Oncology (ASCO) launched CancerLinQ, a platform designed to pool electronic health record data from oncology practices, turning routine patient encounters into a learning system. The platform has since become central to ConcertAI, an oncology-focused AI and real-world data company, which acquired it from ASCO in…
Moderna bets on mRNA’s second act with cancer, autoimmune programs and AI research platform
Calderasib’s real innovation: designed for combinability and potency
Beyond PD-1: The drugs reshaping cancer treatment at ASCO 2026
